Breaking News Instant updates and real-time market news.

MNTA

Momenta

$14.43

0.53 (3.81%)

, ABBV

AbbVie

$83.66

1.12 (1.36%)

16:47
11/06/18
11/06
16:47
11/06/18
16:47

Momenta settles with AbbVie regarding commercializing M923

Momenta Pharmaceuticals (MNTA) announced that it has executed agreements with AbbVie (ABBV) providing license rights for the global launch of M923, Momenta's proposed biosimilar to Humira. Under the terms of the agreements and subject to approval by health regulatory authorities, Momenta may launch M923 in the United States on November 20, 2023 and in Europe upon approval by the European Medicines Agency. Momenta plans to submit a biologics license application for M923 to the FDA in Q4 of 2018 and a marketing authorization application in the European Union in the first half of 2019.

MNTA

Momenta

$14.43

0.53 (3.81%)

ABBV

AbbVie

$83.66

1.12 (1.36%)

  • 07

    Nov

MNTA Momenta
$14.43

0.53 (3.81%)

06/12/18
CANT
06/12/18
INITIATION
CANT
Cantor expands Specialty Pharmaceuticals coverage with eight names
Cantor Fitzgerald analyst Brandon Folkes last night rolled out coverage on eight names in the Specialty Pharmaceuticals space. He initiated coverage of AcelRx (ACRX), ANI Pharmaceuticals (ANIP), Biohaven Pharmaceutical (BHVN), Collegium Pharmaceutical (COLL), Emergent BioSolutions (EBS), Eagle Pharmaceuticals (EGRX) and Opiant Pharmaceuticals (OPNT) with Overweight ratings. There is still value to be unlocked in these stocks at current valuations with risk/reward profiles that remain to the upside, Folkes told investors in a research note. His top picks are ANI Pharmaceuticals, Emergent BioSolutions and Collegium Pharmaceutical. The analyst rounded out his coverage with a Neutral rating on Momenta (MNTA), saying the recent share rally puts him on the sidelines "for now."
09/13/18
STFL
09/13/18
INITIATION
Target $40
STFL
Buy
Momenta assumed with a Buy at Stifel
Stifel analyst Derek Archila assumed Momenta with a Buy rating and a price target of $40, saying the stock offers an investment in an "exciting biotech company that has a pipeline with demonstrated proof-of-mechanism". The analyst expects sentiment on Momenta to shift as it "completes its strategic review, ideally sheds costs/potentially monetizes its legacy businesses, and narrows its focus on its proprietary pipeline M281 and M254.
10/11/18
PIPR
10/11/18
NO CHANGE
PIPR
Overweight
Piper says Momenta update underscores safer profile of Argenx's efgartigimod
Piper Jaffray analyst Edward Tenthoff noted that at Momenta's (MNTA) R&D Day the company shared additional safety data for anti-FcRn antibody M281, disclosing that three subjects in the multiple ascending dose cohort of the Phase 1 study experienced CK elevation and terminated dosing. Also, a 25-30% reduction in serum albumin was reported across single and multiple dosing cohorts, said Tenthoff, who added that neither of these events were observed in Argenx's (ARGX) animal or healthy volunteer studies for efgartigimod. The analyst, who believes efgartigimod produces similar activity without compromising safety and sees the company as about two years ahead of Momenta, keeps an Overweight rating and $154 price target on Argenx shares.
11/05/18
PIPR
11/05/18
INITIATION
Target $35
PIPR
Overweight
Momenta initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Danielle Brill started Momenta Pharmaceuticals with an Overweight rating and $35 price target. The company offers a "rare" biotech investment opportunity as its stock is "super cheap" and its anti-FcRn therapies could be game changing for treating auto-immune diseases, Brill tells investors in a research note. Momenta's proprietary pipeline has "major blockbuster potential and is underappreciated by investors," says the analyst.
ABBV AbbVie
$83.66

1.12 (1.36%)

10/25/18
BMOC
10/25/18
NO CHANGE
Target $192
BMOC
Outperform
Vertex price target lowered to $192 from $204 at BMO Capital
BMO Capital analyst Do Kim lowered his price target on Vertex (VRTX) to $192, saying its in-line Q3 results may be overshadowed by the AbbVie (ABBV) decision to license rights to Galapagos (GLPG) cystic fibrosis program, since the expectation was for the collaboration to dissolve. The analyst adds that while the Galapagos interim data did not make competitive inroads on Vertex therapies, he is still lowering the the FY19 EPS view for the latter to $4.43 from $5.13 on slow ex-U.S. growth amid reimbursement challenges and higher operating expenses. Longer term, Kim keeps his Outperform rating on Vertex.
10/30/18
NOMU
10/30/18
NO CHANGE
Target $140
NOMU
Buy
Galapagos price target raised to $140 from $124 at Nomura Instinet
Nomura Instinet analyst Christopher Marai raised his price target for Galapagos NV to $140 following last week's Q3 results and the sale of its partnered-cystic fibrosis program back to AbbVie (ABBV) for $45M upfront and $200M in milestones. The analyst views the upfront payments as upside to expectations and keeps a Buy rating on Galapagos shares.
11/02/18
PIPR
11/02/18
NO CHANGE
PIPR
AbbVie Q3 results do not convince Piper Jaffray to get off sidelines
Piper Jaffray analyst Christopher Raymond maintained a Neutral rating on AbbVie after the company's Q3 earnings results, which Raymond noted were better than expected. However, the analyst was cautious given management's indication of growing headwinds, which he believes "portend a meaningful downward revision to FY19 consensus." Additionally, Raymond sees AbbVie "married to the prospects of Humira," which he believes now faces international headwinds competing with four biosimilars.
11/06/18
ARGS
11/06/18
NO CHANGE
Target $115
ARGS
Buy
AbbVie price target lowered to $115 from $130 at Argus
Argus analyst David Toung lowered his price target on AbbVie to $115 to reflect the competitive environment for its Humira sales from biosimilars in Europe, but also kept his Buy rating and raised his FY18 EPS view by 9c to $7.91 and FY19 by 12c to $9.00. The analyst says Humira should continue to post "solid growth" in the U.S. markets, and also cites the prospects of its Imbruvica, Venclexta Orilissa and hepatitis C drugs along with its remaining product pipeline. Toung contends that the "incremental sales of new faster-growing products can more than offset the expected decline in overseas sales of Humira".

TODAY'S FREE FLY STORIES

GE

General Electric

$8.04

-0.135 (-1.65%)

, FB

Facebook

$139.55

-4.31 (-3.00%)

08:55
11/19/18
11/19
08:55
11/19/18
08:55
Options
Notable open interest changes for November 19th »

Friday's total…

GE

General Electric

$8.04

-0.135 (-1.65%)

FB

Facebook

$139.55

-4.31 (-3.00%)

NVDA

Nvidia

$164.38

-38.27 (-18.88%)

JD

JD.com

$23.04

-1.18 (-4.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 26

    Nov

  • 28

    Nov

  • 10

    Dec

BKI

Black Knight

$49.77

0.87 (1.78%)

08:55
11/19/18
11/19
08:55
11/19/18
08:55
Conference/Events
Black Knight to host Investor Day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 03

    Dec

ENR

Energizer

$49.91

-1.53 (-2.97%)

, SPB

Spectrum Brands

$59.36

0.87 (1.49%)

08:54
11/19/18
11/19
08:54
11/19/18
08:54
Recommendations
Energizer, Spectrum Brands analyst commentary  »

Energizer price target…

ENR

Energizer

$49.91

-1.53 (-2.97%)

SPB

Spectrum Brands

$59.36

0.87 (1.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

AMZN

Amazon.com

$1,593.59

-26.41 (-1.63%)

, RAD

Rite Aid

$1.22

0.01 (0.83%)

08:50
11/19/18
11/19
08:50
11/19/18
08:50
Recommendations
Amazon.com, Rite Aid, Walgreens Boots Alliance, CVS Health analyst commentary  »

Jefferies uncovers signs…

AMZN

Amazon.com

$1,593.59

-26.41 (-1.63%)

RAD

Rite Aid

$1.22

0.01 (0.83%)

WBA

Walgreens Boots Alliance

$82.54

0.25 (0.30%)

CVS

CVS Health

$79.33

-0.48 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 02

    Dec

  • 04

    Dec

WP

Worldpay

$82.05

-0.62 (-0.75%)

08:50
11/19/18
11/19
08:50
11/19/18
08:50
Recommendations
Worldpay analyst commentary  »

Worldpay elevated to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 26

    Nov

08:50
11/19/18
11/19
08:50
11/19/18
08:50
General news
U.S. equities are back under pressure »

U.S. equities are back…

08:49
11/19/18
11/19
08:49
11/19/18
08:49
Conference/Events
Jefferies defense analysts to hold an analyst/industry conference call »

Defense Analysts provide…

RNG

RingCentral

$76.41

-0.54 (-0.70%)

08:49
11/19/18
11/19
08:49
11/19/18
08:49
Upgrade
RingCentral rating change  »

RingCentral upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAS

Masco

$31.29

-0.1 (-0.32%)

08:47
11/19/18
11/19
08:47
11/19/18
08:47
Recommendations
Masco analyst commentary  »

Masco portfolio offers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCON

TRACON Pharmaceuticals

$1.30

0.005 (0.39%)

08:46
11/19/18
11/19
08:46
11/19/18
08:46
Hot Stocks
TRACON Pharmaceuticals TRC102, Temodar trial does not meet primary endpoint »

TRACON Pharmaceuticals …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CFR

Cullen/Frost

$101.35

0.11 (0.11%)

08:46
11/19/18
11/19
08:46
11/19/18
08:46
Conference/Events
Cullen/Frost has a conference call hosted by SunTrust »

SunTrust Analyst Demba…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

PINC

Premier

$39.60

-0.26 (-0.65%)

08:45
11/19/18
11/19
08:45
11/19/18
08:45
Recommendations
Premier analyst commentary  »

Baird sees Premier shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAX

Baxter

$66.49

0.68 (1.03%)

, ACRX

AcelRx

$2.92

0.07 (2.46%)

08:45
11/19/18
11/19
08:45
11/19/18
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

BAX

Baxter

$66.49

0.68 (1.03%)

ACRX

AcelRx

$2.92

0.07 (2.46%)

XOP

SPDR Oil Exploration and Production Fund

$34.75

-0.055 (-0.16%)

HEAR

Turtle Beach

$15.17

0.15 (1.00%)

NWL

Newell Brands

$21.69

0.32 (1.50%)

EBIX

Ebix

$51.54

1.83 (3.68%)

CNAT

Conatus

$4.82

0.16 (3.43%)

TRVN

Trevena

$0.64

-0.0056 (-0.87%)

EMR

Emerson

$69.68

0.86 (1.25%)

HUYA

Huya

$17.68

-0.45 (-2.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 05

    Dec

  • 11

    Dec

BB

BlackBerry

$8.97

0.12 (1.36%)

08:43
11/19/18
11/19
08:43
11/19/18
08:43
Upgrade
BlackBerry rating change  »

BlackBerry upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSNN

Fusion

$2.42

-0.2 (-7.63%)

08:42
11/19/18
11/19
08:42
11/19/18
08:42
Hot Stocks
Fusion awarded $720,000 cloud solutions contract from Asian fast food chain »

Fusion announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

SFIX

Stitch Fix

$26.83

-0.09 (-0.33%)

08:41
11/19/18
11/19
08:41
11/19/18
08:41
Initiation
Stitch Fix initiated  »

Stitch Fix initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

CARG

CarGurus

$38.76

0.31 (0.81%)

08:41
11/19/18
11/19
08:41
11/19/18
08:41
Initiation
CarGurus initiated  »

CarGurus initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

ATRA

Atara Biotherapeutics

$37.28

1.46 (4.08%)

08:39
11/19/18
11/19
08:39
11/19/18
08:39
Hot Stocks
Atara Biotherapeutics announces publication of Phase 1 ATA190 results »

Atara Biotherapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

MBTF

MBT Financial

$11.25

0.03 (0.27%)

, FRME

First Merchants

$41.23

0.06 (0.15%)

08:39
11/19/18
11/19
08:39
11/19/18
08:39
Upgrade
MBT Financial, First Merchants rating change  »

Sandler O'Neill…

MBTF

MBT Financial

$11.25

0.03 (0.27%)

FRME

First Merchants

$41.23

0.06 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADVM

Adverum Biotechnologies

$3.83

0.095 (2.55%)

08:35
11/19/18
11/19
08:35
11/19/18
08:35
Hot Stocks
Adverum Biotechnologies announces first patient dosed in OPTIC trial »

Adverum Biotechnologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

MLNX

Mellanox

$93.83

0.34 (0.36%)

, LN

Line Corp.

$28.48

-0.23 (-0.80%)

08:35
11/19/18
11/19
08:35
11/19/18
08:35
Hot Stocks
Line Corp. collaborates with Mellanox, Cumulus Networks for messaging platform »

Mellanox Technologies…

MLNX

Mellanox

$93.83

0.34 (0.36%)

LN

Line Corp.

$28.48

-0.23 (-0.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

08:35
11/19/18
11/19
08:35
11/19/18
08:35
General news
Oil Action: NYMEX crude »

Oil Action: NYMEX crude…

FRME

First Merchants

$41.23

0.06 (0.15%)

08:33
11/19/18
11/19
08:33
11/19/18
08:33
Upgrade
First Merchants rating change  »

Sandler ONeill upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PVH

PVH Corp.

$115.51

-1.84 (-1.57%)

08:33
11/19/18
11/19
08:33
11/19/18
08:33
Recommendations
PVH Corp. analyst commentary  »

PVH Corp. price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

CLX

Clorox

$162.02

1.51 (0.94%)

08:31
11/19/18
11/19
08:31
11/19/18
08:31
Conference/Events
Clorox management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.